Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Blog

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio Co. (GBIO) came out with a quarterly loss of $3.12 per share versus the Zacks Consensus Estimate of a loss of $2.8. This compares to a loss of $3.1 per share a year ago. These figures

Is the Options Market Predicting a Spike in Ashland Stock?
Is the Options Market Predicting a Spike in Ashland Stock?

Investors in Ashland Inc. ASH need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 17, 2025 $40 Callhad some of the highest implied

Surf Air Mobility Inc. (SRFM) Reports Q2 Loss, Beats Revenue Estimates
Surf Air Mobility Inc. (SRFM) Reports Q2 Loss, Beats Revenue Estimates

Surf Air Mobility Inc. (SRFM) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to a loss of $1.96 per share a year ago. These

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago. These figures

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.13 per share a year ago. These

Luminar Technologies, Inc. (LAZR) Reports Q2 Loss, Lags Revenue Estimates
Luminar Technologies, Inc. (LAZR) Reports Q2 Loss, Lags Revenue Estimates

Luminar Technologies, Inc. (LAZR) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to a loss of $2.7 per share a year ago

GCT Semiconductor Holding, Inc. (GCTS) Reports Q2 Loss, Misses Revenue EstimatesPhoto, wide shot, wide-angle lens,  Data analytics provider, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/d1295d04-cceb-4f1c-be2b-32ca46621336.png
GCT Semiconductor Holding, Inc. (GCTS) Reports Q2 Loss, Misses Revenue Estimates

GCT Semiconductor Holding, Inc. (GCTS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.02 per share a year

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat EstimatesPhoto, wide shot, wide-angle lens,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

Verrica Pharmaceuticals Inc. (VRCA) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.7 per share. This compares to a loss of $3.1 per share a

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago. These

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $5.51 per share versus the Zacks Consensus Estimate of a loss of $5.79. This compares to a loss of $14.5 per share a year ago. These

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.82 per share a year ago. These figures

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.33 per share a year ago. These

Intellicheck Mobilisa, Inc. (IDN) Reports Q2 Loss, Tops Revenue Estimates
Intellicheck Mobilisa, Inc. (IDN) Reports Q2 Loss, Tops Revenue Estimates

Intellicheck Mobilisa, Inc. (IDN) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago. These figures

Intapp (INTA) Beats Q4 Earnings and Revenue Estimates
Intapp (INTA) Beats Q4 Earnings and Revenue Estimates

Intapp (INTA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.15 per share a year ago. These figures are

Lumentum (LITE) Q4 Earnings and Revenues Top Estimates
Lumentum (LITE) Q4 Earnings and Revenues Top Estimates

Lumentum (LITE) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.06 per share a year ago. These figures

Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue EstimatesPhoto, wide shot, wide-angle lens,  Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago

Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates
Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago. These figures are

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.2 per share a year ago. These

TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates

TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.21 per share a year ago

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.46 per share a year ago. These

These 3 Companies Shattered Quarterly Records
These 3 Companies Shattered Quarterly Records

The 2025 Q2 earnings cycle continues to wind down, with the vast majority of S&P 500 companies already delivering results. The period has been one of resilience, with overall growth remaining strong

Buying the Best Value Stocks as the Market Hits All-Time Highs
Buying the Best Value Stocks as the Market Hits All-Time Highs

The Nasdaq and the S&P 500 surged to new highs on Tuesday as Wall Street ramps up its bets on interest rate cuts after a slightly cooler-than-expected July inflation print.

The other market-moving

Air Lease Shares Up 4.8% Since Q2 Earnings & Revenues Top Estimates
Air Lease Shares Up 4.8% Since Q2 Earnings & Revenues Top Estimates

Shares of Air Lease Corporation (AL) have gained 4.8% since its second-quarter 2025 earnings release on Aug. 4, 2025. The uptick can be attributed to the better-than-expected earnings and revenue

Circle Internet Group, Inc. (CRCL) Reports Q2 Earnings: What Key Metrics Have to Say
Circle Internet Group, Inc. (CRCL) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2025, Circle Internet Group, Inc. (CRCL) reported revenue of $658.08 million, representing no change compared to the same period last year. EPS came in at $1.02, compared

Sea Limited (SE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Sea Limited (SE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2025, Sea Limited Sponsored ADR (SE) reported revenue of $5.36 billion, up 37.2% over the same period last year. EPS came in at $0.85, compared to $0.46 in the year-ago